This is the authors' abstract. We don't add key points for this paper.
Purpose The association between mRNA expression of 13 candidate genes in surgical breast cancer, molecular tumor subtypes and response to neoadjuvant chemotherapy has been investigated in order to identify potential markers with predictive and prognostic value. Methods Tumor pretreatment core biopsies of 92 breast cancer patients treated with neoadjuvant chemotherapy were submitted to gene expression profiling. Medians and percentiles of mRNA expression for each gene were calculated and correlated to molecular tumor subtype and pathological response. Results Positive-hormone receptor (HR) tumors showed significantly higher mRNA levels of AXL (p = 0.006), FGFR1 (p = 0.006), RAP80 (p = 0.007), GAS6 (p = 0.05), BTRCP (p = 0.003) and ZNF217 (p = 0.005). A significant association between gene expression and pathological complete response (pCR) was observed for four genes; AXL (p = 0.03), FGFR1 (p = 0.018), YAP (p = 0.023), BRCA1 (p = 0.027). Multivariate analysis identified low levels of AXL and BRCA1 mRNA as independent factors associated with pCR, with an OR 14.03 (CI95% 1.44-136.61) in AXL and 7.07 (CI95% 1.41–35.43) in BRCA1 . The expression signature combining BRCA1 and AXL low levels associated with pCR in 100% of the cases (p < 0.001). Conclusion A two-gene mRNA expression signature including AXL and BRCA1 associates with pCR to neoadjuvant chemotherapy and can have predictive value.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Baulies et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: